PharmDr. Martin Čulen, Ph.D.

Assistant professor, Department of Internal Medicine, Hematology and Oncology

correspondence Address:
Jihlavská 340/20, 625 00 Brno

office: bldg. F01B2/156
Kamenice 126/3
625 00 Brno

phone:	+420 532 23 4641
e‑mail:

social and academic networks:

Basic information

Supervision

Qualifications

Publications

Type

Total number of publications: 68

2025

Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation

BUŠA Daniel HERUDKOVÁ Zdeňka HÝL Jan VLAŽNÝ Jakub SOKOL Filip MATULOVÁ Květoslava FOLTA Adam HYNŠT Jakub VOJTOVA Lucy KŘEN Leoš REPKO Martin RÁČIL Zdeněk MAYER Jiří ČULEN Martin

Article in Periodical

Molecular oncology, year: 2025, DOI

2024

ANALYSIS OF ALTERNATIVE THERAPEUTIC OPTIONS FOR ACUTE MYELOID LEUKEMIA PATIENTS RESISTANT TO VENETOCLAX BASED ON DRUG SCREENING AND EXPRESSION PROFILING

STYLIANOU Filio LADUNGOVÁ Adriana HÝL Jan BUŠA Daniel ČULEN Martin WEINBERGEROVÁ Barbora MAYER Jiří ŠMÍDA Michal

Conference abstract

Year: 2024, type: Conference abstract
IDENTIFICATION OF CHRONIC MYELOID LEUKEMIA STEM CELLS AT DIAGNOSIS AND EARLY FOLLOW-UP

ČULEN Martin ROMŽOVÁ Marianna SMITALOVÁ Dagmar LOJA Tomáš BUŠA Daniel VENGLÁŘ Ondřej HERUDKOVÁ Zdeňka BORSKÝ Marek TAUŠ Petr REIGL Tomáš PLEVOVÁ Karla ŠMEJKAL Jiří ŽÁČKOVÁ Daniela STEJSKAL L. RÁČIL Zdeněk MAYER Jiří

Conference abstract

Year: 2024, type: Conference abstract
IN VITRO CULTURE OF ACUTE MYELOID LEUKEMIA: EFFECT OF MEDIA COMPONENTS, SMALL INHIBITORS, AND FEEDER CELLS

HÝL Jan BUČKOVÁ V. SLAMENÍKOVÁ T. ROKYTOVÁ M. MAYER Jiří ČULEN Martin

Conference abstract

Year: 2024, type: Conference abstract
Novel casein kinase 1 alpha inhibitors for the treatment of resistant AML and solid tumors

JANOVSKÁ Pavlína RADASZKIEWICZ Tomasz Witold PROCHAZKOVA P PRIŠTICOVÁ Ingrid PLEŠINGEROVÁ Hana ČULEN Martin ŠMÍDA Michal BUŠA Daniel LADUNGOVÁ Adriana MAIER Lukáš HAVEL Štěpán MAYER Jiří SCHEER A PARUCH Kamil BRYJA Vítězslav

Conference abstract

Year: 2024, type: Conference abstract
ROBUST ACUTE MYELOID LEUKEMIA ENGRAFTMENT IN HUMANIZED SCAFFOLDS USING INJECTABLE BIOMATERIALS AND INTRAVENOUS XENOTRANSPLANTATION

BUŠA Daniel HERUDKOVÁ Zdeňka HÝL Jan VLAŽNÝ Jakub SOKOL F. MATULOVÁ Květoslava FOLTA A. HYNŠT Jakub VOJTOVÁ Lucy KŘEN Leoš REPKO Martin RÁČIL Zdeněk MAYER Jiří ČULEN Martin

Conference abstract

Year: 2024, type: Conference abstract

2023

AML engraftment in humanized ossicles is not governed by biomaterial selection.

ČULEN Martin BUŠA Daniel HERUDKOVÁ Zdeňka HÝL Jan VLAŽNÝ Jakub MATULOVÁ Květoslava REPKO Martin VOJTOVÁ Lucy MAYER Jiří

Conference abstract

Year: 2023, type: Conference abstract
Biomaterial selection does not affect AML engraftment in humanized ossicles.

ČULEN Martin LOJA Tomáš BUŠA Daniel HERUDKOVÁ Zdeňka HÝL Jan VLAŽNÝ Jakub LIŠKOVÁ K. REPKO Martin VOJTOVÁ Lucy MAYER Jiří

Conference abstract

Year: 2023, type: Conference abstract
Effect of media components and feeder cells on in vitro culture of acute myeloid leukemia.

HÝL Jan BUČKOVÁ Veronika SLAMĚNÍKOVÁ Tereza ČULEN Martin

Conference abstract

Year: 2023, type: Conference abstract
Identificationof novel therapeutic options for venetoclax-resistant AML cells through drug repurposing.

LADUNGOVÁ Adriana BUŠA Daniel LODHI Yusuf HÝL Jan ČULEN Martin ŠMÍDA Michal

Conference abstract

Year: 2023, type: Conference abstract

Projects

Teaching

10 reasons why you will fall in love with MU

Ask our ambassador

Read about research at MU

PharmDr. Martin Čulen, Ph.D.

2025

Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation

2024

ANALYSIS OF ALTERNATIVE THERAPEUTIC OPTIONS FOR ACUTE MYELOID LEUKEMIA PATIENTS RESISTANT TO VENETOCLAX BASED ON DRUG SCREENING AND EXPRESSION PROFILING

IDENTIFICATION OF CHRONIC MYELOID LEUKEMIA STEM CELLS AT DIAGNOSIS AND EARLY FOLLOW-UP

IN VITRO CULTURE OF ACUTE MYELOID LEUKEMIA: EFFECT OF MEDIA COMPONENTS, SMALL INHIBITORS, AND FEEDER CELLS

Novel casein kinase 1 alpha inhibitors for the treatment of resistant AML and solid tumors

ROBUST ACUTE MYELOID LEUKEMIA ENGRAFTMENT IN HUMANIZED SCAFFOLDS USING INJECTABLE BIOMATERIALS AND INTRAVENOUS XENOTRANSPLANTATION

2023

AML engraftment in humanized ossicles is not governed by biomaterial selection.

Biomaterial selection does not affect AML engraftment in humanized ossicles.

Effect of media components and feeder cells on in vitro culture of acute myeloid leukemia.

Identificationof novel therapeutic options for venetoclax-resistant AML cells through drug repurposing.